Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695308 | 0.98 | ALDH1A1 (0.51) | ALDH1A1LMNAGPR84PTGS2GPR35 | |
| SCHEMBL6691527 | 0.94 | ALDH1A1 (0.53) | ALDH1A1LMNAGPR84MAPTNPSR1 | |
| SCHEMBL11023368 | 0.84 | HPGD (0.56) | ALDH1A1GPR84PTGS2GPR35MAPT | |
| SCHEMBL30372303 | 0.84 | GPR35 (0.48) | ALDH1A1LMNAGPR84PTGS2GPR35 | |
| SCHEMBL11453552 | 0.83 | MAPT (0.61) | ALDH1A1LMNAGPR84PTGS2GPR35 | |
| SCHEMBL11718951 | 0.83 | DAO (0.58) | ALDH1A1GPR84PTGS2GPR35MAPT | |
| SCHEMBL11024967 | 0.83 | DAO (0.58) | ALDH1A1GPR84PTGS2GPR35MAPT | |
| SCHEMBL15177362 | 0.83 | MAPT (0.61) | ALDH1A1LMNAGPR84PTGS2GPR35 | |
| SCHEMBL1863292 | 0.83 | ALDH1A1 (0.46) | ALDH1A1LMNAGPR84PTGS2MAPT | |
| SCHEMBL6143579 | 0.83 | HPGD (0.58) | ALDH1A1GPR84PTGS2GPR35MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803379-B2 | TREATMENT OF VIRAL, BACTERIAL, PARASITIC, PROLIFERATIVE DISEASES, NEURODEGENERATIVE DISEASES, INFLAMMATORY DISEASES, HEAVY METAL POISONING AND IMMUNOGICAL DISEASES WITH THIOPHENE-2-CARBOXYLIC ACID, 2-FUROIC ACID OR DERIVATIVES | POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) | 2004-10-12 | — | — | US | disclosed |
| US-20040167204-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets | FERNANDEZ-POL JOSE A (US) | 2004-08-26 | — | — | US | disclosed |
| US-20030225155-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets | POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167204-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets | ZFX, ZFR, SLC30A6 | ALDH1A1 1453/4885LMNA 4716/4885GPR84 3245/4885 |
| US-20030225155-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets | ZFX, ZFR, SLC30A6 | ALDH1A1 1314/4885LMNA 4800/4885GPR84 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.